These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 39428639)

  • 1. Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas.
    Sagberg LM; Salvesen Ø; Jakola AS; Thurin E; De Dios E; Nawabi NLA; Kilgallon JL; Bernstock JD; Kavouridis VK; Smith TR; Solheim O
    Acta Oncol; 2024 Oct; 63():798-804. PubMed ID: 39428639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
    Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
    Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Treatment Modalities on Progression-Free Survival and Overall Survival in Molecularly Subtyped World Health Organization Grade II Diffuse Gliomas: A Systematic Review.
    Ghaffari-Rafi A; Samandouras G
    World Neurosurg; 2020 Jan; 133():366-380.e2. PubMed ID: 31473344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Intraoperative Magnetic Resonance Imaging and Other Factors on Surgical Outcomes for Newly Diagnosed Grade II Astrocytomas and Oligodendrogliomas: A Multicenter Study.
    Yahanda AT; Patel B; Shah AS; Cahill DP; Sutherland G; Honeycutt J; Jensen RL; Rich KM; Dowling JL; Limbrick DD; Dacey RG; Kim AH; Leuthardt EC; Dunn GP; Zipfel GJ; Leonard JR; Smyth MD; Shah MV; Abram SR; Evans J; Chicoine MR
    Neurosurgery; 2020 Dec; 88(1):63-73. PubMed ID: 32717067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
    J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current knowledge and treatment strategies for grade II gliomas.
    Narita Y
    Neurol Med Chir (Tokyo); 2013; 53(7):429-37. PubMed ID: 23883553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of DNA ploidy with intraoperative flow cytometry may predict long-term survival of patients with supratentorial low-grade gliomas: Analysis of 102 cases.
    Suzuki A; Maruyama T; Nitta M; Komori T; Ikuta S; Chernov M; Tamura M; Kawamata T; Muragaki Y
    Clin Neurol Neurosurg; 2018 May; 168():46-53. PubMed ID: 29522936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: An analysis of the National Cancer Data Base.
    Jhaveri J; Liu Y; Chowdhary M; Buchwald ZS; Gillespie TW; Olson JJ; Voloschin AD; Eaton BR; Shu HG; Crocker IR; Curran WJ; Patel KR
    Cancer; 2018 Mar; 124(6):1169-1178. PubMed ID: 29205287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult low-grade glioma: 19-year experience at a single institution.
    Youland RS; Brown PD; Giannini C; Parney IF; Uhm JH; Laack NN
    Am J Clin Oncol; 2013 Dec; 36(6):612-9. PubMed ID: 22892428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.
    McGirt MJ; Chaichana KL; Attenello FJ; Weingart JD; Than K; Burger PC; Olivi A; Brem H; Quinoñes-Hinojosa A
    Neurosurgery; 2008 Oct; 63(4):700-7; author reply 707-8. PubMed ID: 18981880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multivariate retrospective analysis of high-grade gliomas: Survival and prognostic factors.
    Shi W; Wang X; Liu S; Zheng Z; Dong L; Jiang X
    Cancer Med; 2024 Aug; 13(15):e7456. PubMed ID: 39118481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.
    Koo T; Lim DH; Seol HJ; Dho YS; Kim IH; Chang JH; Lee J; Jung TY; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S
    J Neurooncol; 2018 Nov; 140(2):445-455. PubMed ID: 30097825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age is associated with unfavorable neuropathological and radiological features and poor outcome in patients with WHO grade 2 and 3 gliomas.
    Krigers A; Demetz M; Thomé C; Freyschlag CF
    Sci Rep; 2021 Aug; 11(1):17380. PubMed ID: 34462493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
    Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 16. Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.
    Youland RS; Schomas DA; Brown PD; Nwachukwu C; Buckner JC; Giannini C; Parney IF; Laack NN
    Neuro Oncol; 2013 Aug; 15(8):1102-10. PubMed ID: 23814262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early prognostic factors related to progression and malignant transformation of low-grade gliomas.
    Jung TY; Jung S; Moon JH; Kim IY; Moon KS; Jang WY
    Clin Neurol Neurosurg; 2011 Nov; 113(9):752-7. PubMed ID: 21889256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
    Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
    J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.
    Ulyte A; Katsaros VK; Liouta E; Stranjalis G; Boskos C; Papanikolaou N; Usinskiene J; Bisdas S
    Neuroradiology; 2016 Dec; 58(12):1197-1208. PubMed ID: 27796446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.